Kim HK - Search Results

1

Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer.

Sun DS, Jeon EK, Won HS, Park JC, Shim BY, Park SY, Hong YS, Kim HK, Ko YH. Sun DS, et al. Among authors: kim hk. Gastric Cancer. 2015 Jul;18(3):644-52. doi: 10.1007/s10120-014-0405-8. Epub 2014 Aug 7. Gastric Cancer. 2015. PMID: 25098925

2

A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancer.

Park SR, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Kim NK, Kang WK, Kim HT, Im SA, Suh JH, Kim HK, Kim HK. Park SR, et al. Among authors: kim dw, kim hk, kim ty, kim ht, kim nk. Oncol Rep. 2004 Nov;12(5):1059-64. Oncol Rep. 2004. PMID: 15492793 Clinical Trial.

3

Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.

Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK; Korean Cancer Study Group. Kim TW, et al. Among authors: kim sr, kim hk. Acta Oncol. 2005;44(3):230-5. doi: 10.1080/02841860510029590. Acta Oncol. 2005. PMID: 16076694 Clinical Trial.

4

Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.

Kim YH, Seo HY, Jeen YT, Kim HK, Shim BY, Yang J. Kim YH, et al. Among authors: kim hk. Cancer Chemother Pharmacol. 2009 Jan;63(2):253-60. doi: 10.1007/s00280-008-0734-6. Epub 2008 May 21. Cancer Chemother Pharmacol. 2009. PMID: 18493761 Clinical Trial.

5

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.

Lee KH, Kim MK, Kim YH, Ryoo BY, Lim HY, Song HS, Kim HK, Lee MA, Im SA, Chang HM, Cho JY, Zang DY, Kim BS, Kim JS. Lee KH, et al. Among authors: kim yh, kim bs, kim hk, kim js, kim mk. Cancer Chemother Pharmacol. 2009 Jul;64(2):317-25. doi: 10.1007/s00280-008-0873-9. Epub 2008 Nov 26. Cancer Chemother Pharmacol. 2009. PMID: 19034448 Clinical Trial.

6

The efficacy and safety of Padexol (paclitaxel) and cisplatin for treating advanced non-small cell lung cancer.

Kim HK, Kim JS, Ryoo HM, Shin DG, Shim BY, Park KH, Bae SH, Kim CH. Kim HK, et al. Among authors: kim ch, kim js. Cancer Res Treat. 2006 Apr;38(2):66-71. doi: 10.4143/crt.2006.38.2.66. Epub 2006 Apr 30. Cancer Res Treat. 2006. PMID: 19771262 Free PMC article.

7

A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.

Rhee CK, Lee SH, Kim JS, Kim SJ, Kim SC, Kim YK, Kang HH, Yoon HK, Song JS, Moon HS, Kim JW, Kim CH, Shim BY, Kim HK, Sun DS, Kim KH. Rhee CK, et al. Among authors: kim sc, kim yk, kim hk, kim ch, kim sj, kim js, kim jw, kim kh. Lung Cancer. 2011 Apr;72(1):64-7. doi: 10.1016/j.lungcan.2010.07.003. Epub 2010 Sep 15. Lung Cancer. 2011. PMID: 20832894 Clinical Trial.

8

Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis.

Chun SH, Lee JE, Park MH, Kang JH, Kim YK, Wang YP, Park JK, Kim HK. Chun SH, et al. Among authors: kim yk, kim hk. Cancer Res Treat. 2011 Dec;43(4):217-24. doi: 10.4143/crt.2011.43.4.217. Epub 2011 Dec 27. Cancer Res Treat. 2011. PMID: 22247706 Free PMC article.

9

Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.

Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group. Sun JM, et al. Among authors: kim yh, kim bs, kim hk, kim sw. Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6. Cancer. 2012. PMID: 22674612 Free article. Clinical Trial.

10

A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.

Yang YJ, Park JC, Kim HK, Kang JH, Park SY. Yang YJ, et al. Among authors: kim hk. Anticancer Res. 2013 May;33(5):2115-22. Anticancer Res. 2013. PMID: 23645763 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,015 results

Search Page

Filters